Original paper

Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency

Volume: 127, Issue: 8, Pages: 3126 - 3135
Published: Jul 17, 2017
Abstract
The histone deacetylase (HDAC) inhibitor vorinostat (VOR) can increase HIV RNA expression in vivo within resting CD4+ T cells of aviremic HIV+ individuals. However, while studies of VOR or other HDAC inhibitors have reported reversal of latency, none has demonstrated clearance of latent infection. We sought to identify the optimal dosing of VOR for effective serial reversal of HIV latency.In a study of 16 HIV-infected, aviremic individuals, we...
Paper Details
Title
Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency
Published Date
Jul 17, 2017
Volume
127
Issue
8
Pages
3126 - 3135
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.